UNDBIO , a Korean pharmaceutical company that provides diabetic care solutions, has officially arrived in Montgomery County, Md.  to open its new U.S. research and development headquarters.

The company has leased a 25,000 square-foot facility in Rockville, where it will build out a state-of-the-art laboratory and R&D operations. Located at 12441 Parklawn Drive, the company is expected to begin working on its insulin product next year.

By locating in Montgomery County, UNDBIO will have close proximity to the U.S. FDA, which will need to approve the company’s insulin samples before hitting the pharmaceutical market.

The news of the U.S. headquarters was originally announced during Governor Larry Hogan’s final trade mission in Asia .

“I am happy to establish our relationship with the state of Maryland to undertake the research and development required to produce affordable insulin and insulin analogues for the diabetic population around the globe,” UNDBIO’s Chairman Jun Yong-soo said in a press release . “We look forward to developing high paying biotech jobs for Maryland, and would welcome other partners into our global insulin project.”